{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T13:33:38Z","timestamp":1780407218962,"version":"3.54.1"},"reference-count":15,"publisher":"The Endocrine Society","issue":"12","license":[{"start":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T00:00:00Z","timestamp":1729728000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 AR073191"],"award-info":[{"award-number":["R01 AR073191"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 AR075042"],"award-info":[{"award-number":["P30 AR075042"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"NIH's National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["1UL1TR002541-01"],"award-info":[{"award-number":["1UL1TR002541-01"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Aging of the general population has led to a substantial increase in the prevalence of osteoporosis over the past decades. While there are effective pharmacological agents that increase bone formation, decrease bone resorption, and decrease fracture risk, they do not uniformly cure osteoporosis. This has prompted investigations to examine whether combination therapy (COMBO) with these agents can result in an additive benefit. Since concomitant therapy with denosumab and teriparatide has shown promise in this respect, investigations were undertaken to explore whether the changes in osteogenic phenotype could provide insight into the cellular and molecular mechanism of this effect.<\/jats:p>\n               <jats:p>Investigations were performed in postmenopausal women receiving denosumab, teriparatide, or both for 3 months. Histomorphometric parameters were the primary outcome, while exploratory studies examined RNA expression in bone biopsies as well as in sorted and cultured bone marrow stromal cells (BMSCs). Osteogenic colony forming units of BMSCs were also evaluated. The studies demonstrated that COMBO results in an increase in osteoprogenitors, evidenced by an increase in osteoblastic colony-forming units. This was associated with an increased in BMSC expression of LGR6 (leucine-rich repeat containing G protein\u2013coupled receptor 6), a stem cell marker and activator of the canonical Wnt signaling pathway. These data suggest that enhancement of canonical Wnt signaling contributes to the increase in osteoprogenitors and consequently an increase in bone density in postmenopausal women receiving COMBO for osteoporosis.<\/jats:p>","DOI":"10.1210\/endocr\/bqae142","type":"journal-article","created":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T12:43:28Z","timestamp":1729773808000},"source":"Crossref","is-referenced-by-count":5,"title":["Evaluation of Osteogenic Phenotype in Postmenopausal Women Receiving Anabolic and Antiresorptive Osteoporosis Therapies"],"prefix":"10.1210","volume":"165","author":[{"given":"Margaret M","family":"Kobelski","sequence":"first","affiliation":[{"name":"Endocrine Unit, Massachusetts General Hospital , Boston, MA 02114 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabashini K","family":"Ramchand","sequence":"additional","affiliation":[{"name":"Endocrine Unit, Massachusetts General Hospital , Boston, MA 02114 ,","place":["USA"]},{"name":"Harvard Medical School , Boston, MA 02115 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joy N","family":"Tsai","sequence":"additional","affiliation":[{"name":"Endocrine Unit, Massachusetts General Hospital , Boston, MA 02114 ,","place":["USA"]},{"name":"Harvard Medical School , Boston, MA 02115 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin Z","family":"Leder","sequence":"additional","affiliation":[{"name":"Endocrine Unit, Massachusetts General Hospital , Boston, MA 02114 ,","place":["USA"]},{"name":"Harvard Medical School , Boston, MA 02115 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5845-5479","authenticated-orcid":false,"given":"Marie B","family":"Demay","sequence":"additional","affiliation":[{"name":"Endocrine Unit, Massachusetts General Hospital , Boston, MA 02114 ,","place":["USA"]},{"name":"Harvard Medical School , Boston, MA 02115 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2024,10,24]]},"reference":[{"issue":"3","key":"2024112608404947600_bqae142-B1","doi-asserted-by":"crossref","first-page":"dgaa048","DOI":"10.1210\/clinem\/dgaa048","article-title":"Pharmacological management of osteoporosis in postmenopausal women: an endocrine society guideline update","volume":"105","author":"Shoback","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2024112608404947600_bqae142-B2","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1210\/jc.2015-4181","article-title":"Differential effects of teriparatide and denosumab on intact PTH and bone formation indices: AVA osteoporosis study","volume":"101","author":"Dempster","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2024112608404947600_bqae142-B3","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1359\/jbmr.070906","article-title":"Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure","volume":"23","author":"Recker","year":"2008","journal-title":"J Bone Miner Res"},{"issue":"3","key":"2024112608404947600_bqae142-B4","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/S8756-3282(03)00202-3","article-title":"Anabolic and catabolic bone effects of human parathyroid hormone (1-34) are predicted by duration of hormone exposure","volume":"33","author":"Frolik","year":"2003","journal-title":"Bone"},{"issue":"3","key":"2024112608404947600_bqae142-B5","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1002\/jbmr.238","article-title":"Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis","volume":"26","author":"Cosman","year":"2011","journal-title":"J Bone Miner Res"},{"issue":"13","key":"2024112608404947600_bqae142-B6","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1056\/NEJMoa035725","article-title":"The effects of parathyroid hormone, alendronate, or both in men with osteoporosis","volume":"349","author":"Finkelstein","year":"2003","journal-title":"N Engl J Med"},{"issue":"5","key":"2024112608404947600_bqae142-B7","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1210\/jc.2013-4440","article-title":"Two years of denosumab and teriparatide administration in postmenopausal women with osteoporosis (the DATA extension study): a randomized controlled trial","volume":"99","author":"Leder","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2024112608404947600_bqae142-B8","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1016\/j.mayocp.2022.03.011","article-title":"Skeletal aging","volume":"97","author":"Sfeir","year":"2022","journal-title":"Mayo Clin Proc"},{"issue":"3","key":"2024112608404947600_bqae142-B9","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.bone.2011.12.014","article-title":"Characterization of mesenchymal progenitor cells isolated from human bone marrow by negative selection","volume":"50","author":"Modder","year":"2012","journal-title":"Bone"},{"issue":"4","key":"2024112608404947600_bqae142-B10","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"issue":"3","key":"2024112608404947600_bqae142-B11","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s12020-020-02248-x","article-title":"Targeted next generation sequencing of nine osteoporosis-related genes in the Wnt signaling pathway among Chinese postmenopausal women","volume":"68","author":"Li","year":"2020","journal-title":"Endocrine"},{"key":"2024112608404947600_bqae142-B12","doi-asserted-by":"crossref","first-page":"116267","DOI":"10.1016\/j.bone.2021.116267","article-title":"Mouse LGR6 regulates osteogenesis in vitro and in vivo through differential ligand use","volume":"155","author":"Khedgikar","year":"2022","journal-title":"Bone"},{"key":"2024112608404947600_bqae142-B13","doi-asserted-by":"crossref","first-page":"116681","DOI":"10.1016\/j.bone.2023.116681","article-title":"Wnt-associated adult stem cell marker Lgr6 is required for osteogenesis and fracture healing","volume":"169","author":"Doherty","year":"2023","journal-title":"Bone"},{"issue":"5-6","key":"2024112608404947600_bqae142-B14","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1101\/gad.311068.117","article-title":"Stem cell niche-specific Ebf3 maintains the bone marrow cavity","volume":"32","author":"Seike","year":"2018","journal-title":"Genes Dev"},{"issue":"25","key":"2024112608404947600_bqae142-B15","doi-asserted-by":"crossref","first-page":"e2026176118","DOI":"10.1073\/pnas.2026176118","article-title":"The effect of parathyroid hormone on osteogenesis is mediated partly by osteolectin","volume":"118","author":"Zhang","year":"2021","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/endo\/advance-article-pdf\/doi\/10.1210\/endocr\/bqae142\/60016172\/bqae142.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/endo\/article-pdf\/165\/12\/bqae142\/60813084\/bqae142.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/endo\/article-pdf\/165\/12\/bqae142\/60813084\/bqae142.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T08:41:45Z","timestamp":1732610505000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/endo\/article\/doi\/10.1210\/endocr\/bqae142\/7833662"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,24]]},"references-count":15,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,10,30]]}},"URL":"https:\/\/doi.org\/10.1210\/endocr\/bqae142","relation":{},"ISSN":["1945-7170"],"issn-type":[{"value":"1945-7170","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,12]]},"published":{"date-parts":[[2024,10,24]]},"article-number":"bqae142"}}